

COMPLETE MICROBIOME MAPPING






General Macroscopic Description

	Result	Markers
Stool Colour	Brown	Colour - Brown is the colour of normal stool. Other colours may indicate abnormal gut health.
Stool Form	Semi-formed	Form -Sample form is categorised using the Bristol stool chart. A comment on stool appearance can be found in the comments section.
Mucous	Not Detected	Mucous - Mucous production may indicate the presence of an infection and/or inflammation.
Occult Blood	Negative	Blood (Macro) - The presence of blood in the stool may be the result of several causes besides colorectal bleeding, including hemorrhoids or gastrointestinal infection.

Short Chain Fatty Acids

Result Range Units









Methodology: GC/MS

Short Chain Fatty Acids, Beneficial	137	> 13.6	umol/g	
Butyrate	18.7	10.8 - 33.5	%	
Acetate	58.9	44.5 - 72.4	%	
Propionate	20.5	0.0 - 32.0	%	
Valerate	1.9	0.5 - 7.0	%	

GIT Functional Markers

Result Range Units

Methodology: FEIA, EIA, CLIA, pH electrode

Calprotectin.	25.0	0.0 - 50.0	ug/g	
Pancreatic Elastase	558.0	> 200.0	ug/g	
Secretory (slgA)	647.6	510.0 - 2040.0	ng/mL	
Zonulin	44.1	0.0 - 107.0	ng/mL	
Beta glucuronidase	3298.5	368.0 - 6266.0	U/g	
Steatocrit	16.0 *H	0.0 - 10.0	%	
a-Transglutaminase IgA	26.0	0.0 - 100.0	units/L	
pH	6.7	6.3 - 7.7		

Microbiome Mapping Summary

Parasites & Worms

Blastocystis hominis.

Bacteria & Viruses

Streptococcus salivarius.
Methanobrevibacter smithii

Fungi and Yeasts

Key Phyla Microbiota

Firmicutes:Bacteroidetes Ratio

0.48 < 1.00

RATIO



Relative Commensal Abundance of the 6 Phyla groups can be found on page 5 of this report





4009656

Parasites and Worms.	Result	Range	Units
----------------------	--------	-------	-------

Parasitic Organisms

Cryptosporidium species	<dl	< 1.0	x10 ⁵ org/g	
Entamoeba histolytica.	<dl	< 1.0	x10 ⁵ org/g	
Giardia intestinalis	<dl	< 1.0	x10 ⁵ org/g	
Blastocystis hominis.	4.1 *H	< 1.0	x10 ⁵ org/g	
Dientamoeba fragilis.	<dl	< 1.0	x10 ⁵ org/g	
Endolimax nana	<dl	< 1.0	x10 ⁵ org/g	
Entamoeba coli.	<dl	< 5.0	x10 ⁵ org/g	
Pentatrichomonas hominis	<dl	< 1.0	x10 ⁵ org/g	

Worms

Ancylostoma duodenale, Roundworm	Not Detected		
Ascaris lumbricoides, Roundworm	Not Detected	Necator americanus, Hookworm	Not Detected
Trichuris trichiura, Whipworm	Not Detected	Enterobius vermicularis, Pinworm	Not Detected
Enterocytozoon spp	Not Detected	Hymenolepis spp, Tapeworm	Not Detected
Strongyloides spp, Roundworm	Not Detected	Taenia species, Tapeworm	Not Detected

Comment: Not Detected results indicate the absence of detectable DNA in the sample for the worms reported.
NOTE: Reflex testing is performed on clinically indicated samples

Opportunistic Bacteria/Overgrowth	Result	Range	Units
-----------------------------------	--------	-------	-------

Bacillus species.	<dl	< 1.00	x10 ⁴ CFU/g	
Enterococcus faecalis	<dl	< 1.00	x10 ⁵ CFU/g	
Enterococcus faecium	<dl	< 1.00	x10 ⁵ CFU/g	
Morganella species	<dl	< 1.00	x10 ⁵ CFU/g	
Pseudomonas species	<dl	< 1.00	x10 ⁴ CFU/g	
Pseudomonas aeruginosa.	<dl	< 3.00	x10 ⁴ CFU/g	
Staphylococcus species	<dl	< 1.00	x10 ³ CFU/g	
Staphylococcus aureus	<dl	< 5.00	x10 ³ CFU/g	
Streptococcus agalactiae.	<dl	< 3.00	x10 ⁴ CFU/g	
Streptococcus anginosus.	<dl	< 1.00	x10 ⁶ CFU/g	
Streptococcus mutans.	<dl	< 1.00	x10 ⁴ CFU/g	
Streptococcus oralis.	0.85	< 1.00	x10 ⁶ CFU/g	
Streptococcus salivarius.	9.79 *H	< 5.00	x10 ⁶ CFU/g	
Methanobrevibacter smithii	5.00 *H	< 1.00	x10 ⁵ CFU/g	
Desulfovibrio piger	1.35	< 18.00	x10 ⁶ CFU/g	
Enterobacter cloacae complex.	<dl	< 5.00	x10 ⁵ CFU/g	

Potential Autoimmune Triggers

Citrobacter species.	<dl	< 5.00	x10 ⁴ CFU/g	
Citrobacter freundii.	<dl	< 5.00	x10 ⁴ CFU/g	
Klebsiella species	<dl	< 5.00	x10 ³ CFU/g	
Klebsiella pneumoniae.	<dl	< 5.00	x10 ⁵ CFU/g	
Prevotella copri	<dl	< 1.00	x10 ⁹ CFU/g	
Proteus species	<dl	< 5.00	x10 ⁵ CFU/g	
Proteus mirabilis.	<dl	< 1.00	x10 ⁴ CFU/g	
Fusobacterium species	0.30	< 10.00	x10 ⁴ CFU/g	

P: 1300 688 522
E: info@nutripath.com.au

14 ORANA STREET
AIRLIE BEACH QLD 4802

-.RACHEAL LEE (NPINS)
THRIVE HEALTH
SHOP 6/115 SHINGLEY DRIVE
AIRLIE BEACH QLD 4802

LAB ID : 4009656
UR NO. : 6275694
Collection Date : 29-Jul-2024
Received Date: 01-Aug-2024



Mycology	Result	Range	Units	
Candida dubliniensis.	<dl	< 1.00	x10 ⁵ CFU/g	●
Candida glabrata.	<dl	< 1.00	x10 ⁵ CFU/g	●
Candida intermedia.	<dl	< 1.00	x10 ⁵ CFU/g	●
Candida krusei.	<dl	< 1.00	x10 ⁵ CFU/g	●
Candida lambica.	<dl	< 1.00	x10 ⁵ CFU/g	●
Candida lusitanae.	<dl	< 1.00	x10 ⁵ CFU/g	●
Candida parapsilosis.	<dl	< 1.00	x10 ⁵ CFU/g	●
Candida albicans.	<dl	< 1.00	x10 ⁵ CFU/g	●
Candida famata.	<dl	< 1.00	x10 ⁵ CFU/g	●
Candida keyfr.	<dl	< 1.00	x10 ⁵ CFU/g	●
Candida lipolytica.	<dl	< 1.00	x10 ⁵ CFU/g	●
Geotrichum species.	<dl	< 1.00	x10 ⁵ CFU/g	●
Rhodotorula species.	<dl	< 1.00	x10 ⁵ CFU/g	●
Saccharomyces cerevisiae:	<dl	< 1.00	x10 ⁵ CFU/g	●

Bacterial Pathogens	Result	Range	Units	
Aeromonas hydrophila.	<dl	< 1.00	x10 ³ CFU/g	●
Campylobacter species.	<dl	< 1.00	x10 ⁵ CFU/g	●
C. difficile, Toxin A	<dl	< 1.00	x10 ⁴ CFU/g	●
C. difficile, Toxin B	<dl	< 1.00	x10 ⁴ CFU/g	●
Enterohemorrhagic E. coli	<dl	< 1.00	x10 ⁵ CFU/g	●
Enteroinvasive E. coli/Shigella	<dl	< 1.00	x10 ³ CFU/g	●
Enterotoxigenic E. coli LT/ST	<dl	< 1.00	x10 ⁵ CFU/g	●
Shiga-like Toxin E. coli stx1	<dl	< 1.00	x10 ⁴ CFU/g	●
Shiga-like Toxin E. coli stx2	<dl	< 1.00	x10 ⁴ CFU/g	●
Salmonella species.	<dl	< 1.00	x10 ⁵ CFU/g	●
Vibrio species.	<dl	< 1.00	x10 ⁴ CFU/g	●
Yersinia species.	<dl	< 1.00	x10 ⁵ CFU/g	●
Helicobacter pylori	<dl	< 1.0	x10 ³ CFU/g	●

Comment: Helico Pylori virulence factors will be listed below if detected POSITIVE

H.pylori Virulence Factor, babA	Not Detected	H.pylori Virulence Factor, cagA	Not Detected
H.pylori Virulence Factor, dupA	Not Detected	H.pylori Virulence Factor, iceA	Not Detected
H.pylori Virulence Factor, oipA	Not Detected	H.pylori Virulence Factor, vacA	Not Detected
H.pylori Virulence Factor, virB	Not Detected	H.pylori Virulence Factor, virD	Not Detected

Viral Pathogens	Result	Range	Units
Adenovirus 40/41	Not Detected		
Norovirus GI/II	Not Detected		
Rotavirus A	Not Detected		
Sapovirus (I,II,IV,V)	Not Detected		
Astrovirus (hAstro)	Not Detected		

P: 1300 688 522
E: info@nutripath.com.au

-.RACHEAL LEE (NPINS)
THRIVE HEALTH
SHOP 6/115 SHINGLEY DRIVE
AIRLIE BEACH QLD 4802

LAB ID : 4009656
UR NO. : 6275694
Collection Date : 29-Jul-2024
Received Date: 01-Aug-2024



4009656

Normal Bacterial GUT Flora	Result	Range	Units	
<i>Bacteroides fragilis</i>	0.7*L	1.6 - 250.0	x10 ⁵ CFU/g	
<i>Bifidobacterium adolescentis</i>	52.4	4.6 - 1000.0	x10 ⁵ CFU/g	
<i>Bifidobacterium bifidum</i>	<dl*L	4.6 - 1000.0	x10 ⁶ CFU/g	
<i>Bifidobacterium breve</i>	<dl*L	4.6 - 1000.0	x10 ³ CFU/g	
<i>Bifidobacterium longum</i>	0.8*L	4.6 - 1000.0	x10 ⁴ CFU/g	
<i>Enterococcus species</i>	39.4	1.9 - 2000.0	x10 ³ CFU/g	
<i>Escherichia species</i>	409.7	3.7 - 3800.0	x10 ⁴ CFU/g	
<i>Lactobacillus acidophilus</i>	<dl*L	1.7 - 500.0	x10 ³ CFU/g	
<i>Lactobacillus casei</i>	<dl*L	1.7 - 500.0	x10 ³ CFU/g	
<i>Lactobacillus delbrueckii</i>	10.3	1.7 - 500.0	x10 ³ CFU/g	
<i>Lactobacillus plantarum</i>	<dl*L	1.7 - 500.0	x10 ³ CFU/g	
<i>Lactobacillus rhamnosus</i>	1.0*L	1.7 - 500.0	x10 ³ CFU/g	
<i>Lactobacillus salivarius</i>	<dl*L	1.7 - 500.0	x10 ³ CFU/g	
<i>Clostridium species</i>	25.4	5.0 - 50.0	x10 ⁷ CFU/g	
<i>Oxalobacter formigenes</i>	<dl*L	> 5.00	x10 ⁶ CFU/g	
<i>Akkermansia muciniphila</i>	<dl*L	1.00 - 50.00	x10 ⁷ CFU/g	
<i>Faecalibacterium prausnitzii</i>	291.0	200.0 - 3500.0	x10 ⁶ CFU/g	

Actions

	<i>L. plantarum</i> HEAL9	<i>L. paracasei</i> 8700:2	<i>L. plantarum</i> 6595	<i>L. plantarum</i> 299V	<i>L. rhamnosus</i> GG	<i>L. acidophilus</i> LA02	<i>B. animalis</i> subsp. <i>lactis</i> BS01	<i>L. casei</i> LC03	<i>B. breve</i> BR03	<i>L. fermentum</i> LF08	<i>L. crispatus</i> strains	<i>B. animalis</i> subsp. <i>lactis</i> BA05	<i>L. plantarum</i> LP01	<i>L. rhamnosus</i> LR06	<i>B. longum</i> 04	<i>L. fermentum</i> LF16	<i>L. salivarius</i> LS01	<i>B. breve</i> B632	<i>L. fermentum</i> LF10	<i>L. salivarius</i> LS03	<i>L. helveticus</i> Rosell-52	<i>L. rhamnosus</i> Rosell-11	<i>B. longum</i> Rosell-75	<i>S. boulardii</i> CNCM I-1079	<i>S. thermophilus</i> FP4
Intestinal epithelial barrier health																									
Mucous membrane health																									
Normalisation of bowel movements																									
Normalisation of bloating																									
Normalisation of peristalsis																									
Autoimmune immunomodulation																									
Inhibition of pathogenic overgrowth																									
Inactivate microbial toxins																									
Increase infection resistance																									
Th1/Th2 immune cell modulation																									
Staphylococci inhibition																									
Gut-brain axis support																									
GABA production																									
Bone resorption inhibition																									
E. coli inhibition																									
Oxalate degradation																									



P: 1300 688 522
E: info@nutripath.com.au

-.RACHEAL LEE (NPINS)
THRIVE HEALTH
SHOP 6/115 SHINGLEY DRIVE
AIRLIE BEACH QLD 4802

KERR CLAXTON
16-Mar-1987 **Female**

14 ORANA STREET
AIRLIE BEACH QLD 4802






LAB ID : 4009656
UR NO. : 6275694
Collection Date : 29-Jul-2024
Received Date: 01-Aug-2024




4009656

Introduction:


Your gut microbiome is a collective name for the 40 trillion cells and up to 1000 microbial species that include bacteria, viruses, fungi, parasites, and archaea and reside in our gut. The number of gut bacterial cells is approximately equal to the total number of human cells in our body, so if we consider only cell counts, we are only about half human. In terms of gene counts, the microbiome contains about 200 times more genes than the human genome, making bacterial genes responsible for over 99% of our body's gene content! Of all the microbial communities in the human body, the gut microbiome is by far the most dense, diverse, and physiologically important ecosystem to our overall health.

Relative Commensal Abundance	Result	Range	Units
 Bacteroidetes Phylum	66.914	50.000 - 95.000	%
 Firmicutes Phylum	32.161	3.500 - 40.000	%
 Proteobacteria Phylum	0.818	0.050 - 12.500	%
 Actinobacteria Phylum	0.061	0.001 - 4.818	%
 Euryarchaeota Phylum	0.046*H	0.000 - 0.010	%
 Verrucomicrobia Phylum	0.000	0.000 - 2.400	%

Your Phyla:



Healthy Phyla:



References:

NOTE: Relative abundance reference ranges have been based on a healthy population study.

King CH, et., al. (2019) Baseline human gut microbiota profile in healthy people and standard reporting template. PLoS One. 2019 Sep 11;14(9):e0206484.



P: 1300 688 522
E: info@nutripath.com.au

-.RACHEAL LEE (NPINS)
THRIVE HEALTH
SHOP 6/115 SHINGLEY DRIVE
AIRLIE BEACH QLD 4802

KERR CLAXTON
16-Mar-1987 **Female**

14 ORANA STREET
AIRLIE BEACH QLD 4802

LAB ID : 4009656
UR NO. : 6275694
Collection Date : 29-Jul-2024
Received Date: 01-Aug-2024



4009656

Pathogen Summary:

Macroscopy Comment

BROWN coloured stool is considered normal in appearance.

Faecal Occult Blood Negative:

Faecal occult blood has not been detected in this specimen. If the test result is negative and clinical symptoms persist, additional follow-up testing using other clinical methods is recommended.

Metabolism Comment

In a healthy gut Short Chain Fatty Acids (SCFAs) exhibited in the following proportions; Butyrate, Acetate, Propionate (16%:60%:24%).

The primary SCFAs butyrate, propionate and acetate are produced by predominant commensal bacteria via fermentation of soluble dietary fibre and intestinal mucus glycans.

Key producers of SCFAs include *Faecalibacterium prausnitzii*, *Akkermansia muciniphila*, *Bacteroides fragilis*, *Bifidobacterium*, *Clostridium* and *Lactobacillus* Spp.

The SCFAs provide energy for intestinal cells and regulate the actions of specialised mucosal cells that produce anti-inflammatory and antimicrobial factors, mucins that constitute the mucus barriers, and gut active peptides that facilitate appetite regulation and euglycemia. Abnormal SCFAs may be associated with dysbiosis, intestinal barrier dysfunction and inflammatory conditions.



P: 1300 688 522
E: info@nutripath.com.au

-RACHEAL LEE (NPINS)
THRIVE HEALTH
SHOP 6/115 SHINGLEY DRIVE
AIRLIE BEACH QLD 4802

KERR CLAXTON
16-Mar-1987 **Female**

14 ORANA STREET
AIRLIE BEACH QLD 4802

LAB ID : 4009656
UR NO. : 6275694
Collection Date : 29-Jul-2024
Received Date: 01-Aug-2024



4009656

GIT Markers Comment

PANCREATIC ELASTASE: Normal exocrine pancreatic function.

Pancreatic Elastase reflects trypsin, chymotrypsin, amylase and lipase activity.

This test is not affected by supplements of pancreatic enzymes.

Healthy individuals should be producing >500 ug/g of PE-1 under normal/healthy conditions.

PE-1 levels between 200 - 500 ug/g may indicate suboptimal production.

PE-1 levels <200 ug/g indicate clear inadequate production.

The clinician should therefore consider digestive enzyme supplementation if one or more of the following conditions is present:

Loose watery stools, Undigested food in the stools, Post-prandial abdominal pain, Nausea or colicky abdominal pain, Gastroesophageal reflux symptoms, Bloating or food intolerance.

Testing performed by chemiluminescence immunoassay (CLIA).

CALPROTECTIN Normal:

Faecal calprotectin values <50 ug/g are not indicative of inflammation in the gastrointestinal tract. Subjects with low faecal calprotectin levels normally do not need to be further investigated by invasive procedures. In patients with strong clinical indications of intestinal inflammation, repeat testing may be useful.

Test performed by Phadia ELiA Fluorescence enzyme immunoassay (FEIA).

SECRETORY IGA NORMAL:

Secretory IgA is within range.

Secretory IgA represents the first line of defence of the gastrointestinal mucosa and is central to the normal function of the gastrointestinal tract as an immune barrier. Review this level with other pathogenic bacteria and normal commensal flora. Lower levels within reference range should be interpreted clinically.

ZONULIN NORMAL:

Zonulin is a protein that modulates intestinal barrier function. This results is considered normal.

BETA-GLUCURONIDASE NORMAL:

B-Glucuronidase is considered normal and is within reference range.

ELEVATED STEATOCRIT:

The presence of steatorrhea is an indirect indicator of incomplete fat digestion. Consider high dietary fat intake, cholestasis, malabsorption and digestion (diarrhoea, pancreatic or bile salt insufficiency), intestinal dysbiosis, parasites, NSAIDs use, short bowel syndrome, whipple disease, crohn's disease, food allergies & sensitivities.

Treatment:

- o Prebiotic and probiotic supplementation
- o Supplement hydrochloride, digestive enzymes or other digestive aids
- o Investigate underlying causes
- o Investigate food sensitivities and allergies
- o Remove potential irritants
- o Review markers such as pancreatic elastase 1 and calprotectin



P: 1300 688 522
E: info@nutripath.com.au

-.RACHEAL LEE (NPINS)
THRIVE HEALTH
SHOP 6/115 SHINGLEY DRIVE
AIRLIE BEACH QLD 4802

KERR CLAXTON
16-Mar-1987 **Female**

14 ORANA STREET
AIRLIE BEACH QLD 4802

LAB ID : 4009656
UR NO. : 6275694
Collection Date : 29-Jul-2024
Received Date: 01-Aug-2024



4009656

Parasites/Worms Comment

ELEVATED BLASTOCYSTIS HOMINIS LEVEL:

Blastocystis hominis may be the cause of persistent, mild diarrhoea. Although considered endemic, it may also be associated with recent overseas travel. Detection suggests the ingestion of contaminated material or contact with farm animals. Continued symptoms may require further testing for the detection of bacterial, viral and/or parasitic co-pathogens.

TREATMENT SUGGESTIONS:

Mild symptoms are self-limiting.

If treatment is warranted, metronidazole 400 - 750mg (child 12-17mg/kg up to 750mg) three times daily for at least 10 days.

Lower dosages are usually associated with treatment failure.

Paromomycin has also shown to be effective as an alternative treatment option.

Rule out allergy to above medication before prescribing/taking. Consult ID specialist if patient is showing severe symptoms or immunocompromised.

Opportunistic Bacteria Comment

STREPTOCOCCUS SALIVARIUS ELEVATED:

PHYLUM: Firmicutes

DESCRIPTION:

Streptococcus salivarius is a Gram-positive bacterium primarily found in the oral and upper respiratory microbiomes but also present in the gut microbiome. It plays a protective role by producing bacteriocins (BLIS), which inhibit pathogens such as Streptococcus pyogenes. In the gut, S. salivarius contributes to maintaining a balanced microbial environment, supporting overall gut health and enhancing the immune system. Its ability to produce antimicrobial substances helps to prevent the overgrowth of harmful bacteria, promoting a healthy gut microbiome.

METHANOBREVIBACTER SMITHII ELEVATED:

PHYLUM: Euryarchaeota

DESCRIPTION:

Methanobrevibacter smithii is a methane-producing microbe that plays an important role in the gut ecosystem by facilitating carbohydrate fermentation and production of short-chain fatty acids by commensal bacteria. Elevated levels may be associated with abdominal bloating, constipation, flatulence, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), colorectal cancer, diverticulosis or obesity and often correlate with a positive SIBO test.

Methanobrevibacter smithii has also been closely correlated with the presence of Blastocystis hominis.

TREATMENT SUGGESTIONS:

Elimination of methanogenic flora using antibiotic treatment may contribute to therapeutic benefits and include neomycin or rifaximin. Antimicrobial herbs may also be beneficial in treatment (including garlic and oregano). Rule out allergy to above medication before prescribing/taking.

Phyla Microbiota Comment

EURYARCHAEOTA (PHYLUM) ELEVATED:

DESCRIPTION:

Euryarchaeota are a phylum of a diverse range of bacteria, including methanogens, halophiles and sulfate-reducers. Three distinct species within the group of Euryarchaeota have been regularly detected within the human body. Among these is the primary colonizer of the human gut system Methanobrevibacter smithii and the less frequently found species Methanosphaera stadtmanae, while in the oral cavity M. oralis is the predominating methanogenic species. Methanogens support the growth of fermenting bacteria, which themselves could be either true pathogens or at least opportunistic pathogens but also members of the commensal flora.

They may also transform heavy metals or metalloids into volatile methylated derivatives which are known to be more toxic than the original compounds. Elevated Euryarchaeota may be associated with inflammatory bowel disease, Crohn's, irritable bowel syndrome, colorectal cancer, diverticulosis, and obesity. It may also affect short chain fatty acid production and absorption.

TREATMENT SUGGESTIONS: If treatment is warranted, Statins may be used to inhibit methanogenic archaea growth without affecting bacterial numbers. Symptoms may also be treated with dietary modification (low FODMAP) and probiotics.

A lactulose SIBO test may be considered to assess Methanogen levels.



P: 1300 688 522
E: info@nutripath.com.au

-.RACHEAL LEE (NPINS)
THRIVE HEALTH
SHOP 6/115 SHINGLEY DRIVE
AIRLIE BEACH QLD 4802

KERR CLAXTON
16-Mar-1987 **Female**

14 ORANA STREET
AIRLIE BEACH QLD 4802

LAB ID : 4009656
UR NO. : 6275694
Collection Date : 29-Jul-2024
Received Date: 01-Aug-2024



4009656

Normal Bacterial Flora Comment

BACTEROIDES FRAGILIS LOW:

PHYLUM: Bacteroidetes

DESCRIPTION: Bacteroides fragilis is an anaerobic, Gram-negative bacterium. It is part of the normal microbiota of the human colon and is generally commensal. Bacteroides fragilis plays an intricate role in the human colon and usually has a beneficial relationship with the host. Low Bacteroides fragilis levels have been associated with inflammatory bowel disease and Crohn's.

TREATMENT SUGGESTIONS: Treatment may involve the use of probiotics and dietary modification.

BIFIDOBACTERIUM BIFIDUM LOW:

PHYLUM: Actinobacteria

DESCRIPTION:

Bifidobacterium bifidum is a Gram-positive, anaerobic bacterium integral to the human gut microbiota, especially in infants. It ferments a variety of carbohydrates, including human milk oligosaccharides, aiding in digestion, and promoting a healthy gut flora. B. bifidum produces short-chain fatty acids that lower gut pH and inhibit pathogenic bacteria while supporting intestinal cells. It also modulates the immune system, enhancing immune responses and reducing inflammation, and strengthens the intestinal barrier. Clinically, B. bifidum has shown promise in alleviating gastrointestinal disorders.

BIFIDOBACTERIUM BREVE LOW:

PHYLUM: Actinobacteria

DESCRIPTION:

Bifidobacterium breve is a Gram-positive, anaerobic bacterium that is commonly found in the human gastrointestinal tract, particularly in the intestines of infants. B. breve is known for its ability to metabolise various carbohydrates, including human milk oligosaccharides, which is essential for the development of a healthy gut flora in newborns. Studies demonstrate that B. breve exhibits several beneficial properties, including the production of short-chain fatty acids (SCFAs) such as acetate, which contribute to gut health by lowering pH and inhibiting the growth of pathogenic bacteria. Additionally, B. breve may alleviate symptoms of irritable bowel syndrome (IBS) and improve symptoms of atopic dermatitis.

BIFIDOBACTERIUM LONGUM LOW:

PHYLUM: Actinobacteria

DESCRIPTION:

Bifidobacterium longum is a Gram-positive, catalase-negative, rod-shaped bacterium present in the human gastrointestinal tract and one of the Bifidobacterium species. It can induce and regulate immune responses, reduce the expression of inflammatory cytokines, and maintain the normal intestinal barrier function.

Bifidobacterium longum is a clinically effective, well-established, multifunctional probiotic that has a long history of human use in alleviating gastrointestinal, immunological, and infectious diseases such as constipation, antibiotic associated diarrhoea, irritable bowel syndrome and ulcerative colitis. Low levels may be associated with irritable bowel syndrome, asthma, autism, depressive disorder and with pathogenic bacteria infection.

TREATMENT SUGGESTIONS: Treatment may involve the use of Bifidobacterium longum containing probiotics and treatment of any intestinal infections.

LACTOBACILLUS ACIDOPHILUS LOW:

PHYLUM: Firmicutes

DESCRIPTION:

Lactobacillus acidophilus is a Gram-positive, rod-shaped, non-spore-forming bacterium commonly found in the human gut and fermented foods. It plays a key role in oxalate degradation, bowel normalisation and may assist patients with bloating.

TREATMENT SUGGESTIONS:

Consider probiotic supplementation containing L. acidophilus.

LACTOBACILLUS CASEI LOW:



P: 1300 688 522
E: info@nutripath.com.au

-.RACHEAL LEE (NPINS)
THRIVE HEALTH
SHOP 6/115 SHINGLEY DRIVE
AIRLIE BEACH QLD 4802

KERR CLAXTON
16-Mar-1987 **Female**

14 ORANA STREET
AIRLIE BEACH QLD 4802

LAB ID : 4009656
UR NO. : 6275694
Collection Date : 29-Jul-2024
Received Date: 01-Aug-2024



4009656

PHYLUM: Firmicutes

DESCRIPTION:

Lactobacillus casei is a Gram-positive, rod-shaped, non-spore-forming, anaerobic probiotic bacterium involved in the fermentation of foods like cheese and yogurt. It produces antimicrobial substances, enhances gut barrier function, reduces pathogenic bacteria, and modulates the immune system. This bacterium is used to prevent and may assist various forms of diarrhea, including infectious diarrhea, traveller's diarrhea, and antibiotic-associated diarrhea.

TREATMENT SUGGESTIONS:

Consider probiotic supplementation containing *L. casei* and consuming fermented foods such as cheese and yogurt.

LACTOBACILLUS PLANTARUM LOW:

PHYLUM: Firmicutes

DESCRIPTION:

Lactobacillus plantarum is a Gram-positive, non-spore-forming, rod-shaped bacterium. *L. plantarum* plays a crucial role in gut health by enhancing intestinal barrier function, modulating the immune system, and inhibiting pathogenic bacteria. Additionally, it is beneficial for conditions such as irritable bowel syndrome, ulcerative colitis, and high cholesterol.

TREATMENT SUGGESTIONS:

Consider probiotic supplementation containing *L. plantarum*.

LACTOBACILLUS RHAMNOSUS LOW:

PHYLUM: Firmicutes

DESCRIPTION:

Lactobacillus Rhamnosus is a Gram-positive anaerobic bacterium and is one of the most widely used probiotic strains, of which various health effects are well documented including the prevention and treatment of gastro-intestinal infections and diarrhea and even preventing certain allergic symptoms.

Decreased *Lactobacillus rhamnosus* colonisation has been shown to decrease gastro-intestinal health, increasing the risk of gastro-intestinal infections and diarrhea as well as extra-intestinal infections including oral and respiratory health. Studies have also revealed that chronic psychological stress and alcohol use may be associated with a decrease in *Lactobacillus* species, as well as antibiotic / medication use.

TREATMENT SUGGESTIONS: Treatment may involve the use of *Lactobacillus* containing probiotics and treatment of any intestinal infections.

LACTOBACILLUS SALIVARIUS LOW:

PHYLUM: Firmicutes

DESCRIPTION:

Lactobacillus salivarius is a Gram-positive, rod-shaped, non-spore-forming bacterium predominantly found in the human oral cavity, gastrointestinal tract, and vagina. It plays a significant role in maintaining oral and gut health by producing lactic acid and bacteriocins, which inhibit the growth of pathogenic bacteria. *L. salivarius* enhances gut barrier function, modulates the immune system, and helps in the digestion of proteins and complex carbohydrates. It has been studied for its potential benefits in managing conditions such as irritable bowel syndrome (IBS), periodontal disease, and atopic dermatitis, highlighting its importance in promoting overall health and preventing infections.

TREATMENT SUGGESTIONS:

Consider *L. salivarius* as a probiotic strain which may improve intestinal permeability and immune response.

OXOLOBACTER FORMIGENES LOW:

PHYLUM: Proteobacterium

DESCRIPTION:

Oxalobacter formigenes is a Gram negative oxalate-degrading anaerobic bacterium. Oxalate is formed in the liver by amino acid catabolism as well as present in a wide range of foods including tea, coffee, chocolate and certain fruits and vegetables. High concentration of oxalate in the urine is related to the potential formation of calcium oxalate kidney stones. *Oxalobacter Formigenes* is the main known bacterial species involved in oxalate degradation in the gut and maintains oxalate homeostasis. Levels of *O. Formigenes* tends to decrease with age as well as with the use of antibiotics or other drugs. Low levels may be associated with



P: 1300 688 522
E: info@nutripath.com.au

-RACHEAL LEE (NPINS)
THRIVE HEALTH
SHOP 6/115 SHINGLEY DRIVE
AIRLIE BEACH QLD 4802

KERR CLAXTON
16-Mar-1987 **Female**

14 ORANA STREET
AIRLIE BEACH QLD 4802

LAB ID : 4009656
UR NO. : 6275694
Collection Date : 29-Jul-2024
Received Date: 01-Aug-2024



4009656

calcium oxide stone formation, inflammatory bowel disease or Crohn's.

TREATMENT SUGGESTIONS:

Treatment options include probiotic treatment and low oxalate diet modification. Urinary oxalate levels may also need to be investigated.

AKKERMANSIA MUCINIPHILA LOW:

PHYLUM: Verrucomicrobia

DESCRIPTION:

Akkermansia muciniphila is a Gram-negative, strictly anaerobic, non-motile bacterium, often considered a human intestinal symbiont. There is growing evidence to suggest that the prevalence of this bacteria is associated with intestinal homeostasis, immunity, and a healthy gut. Decreased colonisation levels may be associated with obesity, type 2 diabetes, and inflammation.

TREATMENT SUGGESTIONS: Treatment may involve the use of probiotics, treatment of any intestinal infections and dietary modification.



The Four “R” Treatment Protocol

REMOVE	Using a course of antimicrobial, antibacterial, antiviral or anti parasitic therapies in cases where organisms are present. It may also be necessary to remove offending foods, gluten, or medication that may be acting as antagonists. Consider testing IgG96 foods as a tool for removing offending foods.	ANTIMICROBIAL	Oil of oregano, berberine, caprylic acid
		ANTIBACTERIAL	Liquorice, zinc carnosine, mastic gum, tribulus, berberine, black walnut, caprylic acid, oil of oregano
		ANTIFUNGAL	Oil of oregano, caprylic acid, berberine, black walnut
		ANTIPARASITIC	Artemesia, black walnut, berberine, oil of oregano
		ANTIVIRAL	Cat's claw, berberine, echinacea, vitamin C, vitamin D3, zinc, reishi mushrooms
		BIOFILM	Oil of oregano, protease
REPLACE	In cases of maldigestion or malabsorption, it may be necessary to restore proper digestion by supplementing with digestive enzymes.	DIGESTIVE SUPPORT	Betaine hydrochloride, tilactase, amylase, lipase, protease, apple cider vinegar, herbal bitters
REINOCULATE	Recolonisation with healthy, beneficial bacteria. Supplementation with probiotics, along with the use of prebiotics helps re-establish the proper microbial balance.	PREBIOTICS	Slippery elm, pectin, larch arabinogalactans
		PROBIOTICS	Bifidobacterium animalis subsp. lactis, lactobacillus acidophilus, lactobacillus plantarum, lactobacillus casei, bifidobacterium breve, bifidobacterium bifidum, bifidobacterium longum, lactobacillus salivarius subsp. salivarius, lactobacillus paracasei, lactobacillus rhamnosus, Saccharomyces boulardii
REPAIR & REBALANCE	Restore the integrity of the gut mucosa by giving support to healthy mucosal cells, as well as immune support. Address whole body health and lifestyle factors so as to prevent future GI dysfunction.	INTESTINAL MUCOSA IMMUNE SUPPORT	Saccharomyces boulardii, lauric acid
		INTESTINAL BARRIER REPAIR	L-Glutamine, aloe vera, liquorice, marshmallow root, okra, quercetin, slippery elm, zinc carnosine, Saccharomyces boulardii, omega 3 essential fatty acids, B vitamins
		SUPPORT CONSIDERATION	Sleep, diet, exercise, and stress management